Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 92 of 113 for:    Recruiting, Not yet recruiting, Available Studies | Common carotid artery

Relationship Between Endothelial Progenitor Cells and Revascularization Effect of Moyamoya Disease (REPCREMMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03613701
Recruitment Status : Recruiting
First Posted : August 3, 2018
Last Update Posted : January 31, 2019
Sponsor:
Information provided by (Responsible Party):
Affiliated Hospital to Academy of Military Medical Sciences

Brief Summary:
Moyamoya disease is a chronic cerebrovascular disease,The typical pathological manifestations are the stenosis or occlusion of the distal internal carotid artery and/or middle cerebral artery, and the proximal anterior cerebral artery. Meanwhile, the abnormal vascular net, which is the smokey vessel, occurs at the bottom of the brain. Currently the pathogenesis of this disease is unknown. Limited studies have reported the expression of endothelial progenitor cells (EPCs) in moyamoya disease, but the results were inconsistent. Some investigators believe that the number of EPCs in peripheral blood of patients with moyamoya disease is increased, while others believe that the number of EPCs in peripheral blood of moyamoya patients is reduced. Therefore, the investigators need to find a more accurate detection method to confirm the growth of EPC in patients with moyamoya disease. At the same time, whether there is endothelial injury in patients with smoke disease, and the expression of endothelial cells (CEC) in patients with smoke disease, there is no research on this aspect at home and abroad.

Condition or disease
Moyamoya Disease

Detailed Description:

Objective: Detect the expression of endothelial progenitor cells and endothelial cells from peripheral blood of patients with moyamoya disease, and to assess the relationship between clinical characteristics.

Design: A single center study, and planned to enroll 120 patients. The present study was to detect the quantities of EPC from peripheral blood in Moyamoya disease by flow cytometry, and to identify the relationship of endothelial progeIlitor cells and effect of the revascularization on Moyamoya disease. The present study also use cerebral ischemia animal model foe intervention experiment, to explore whether EPC can promote vascular remodeling effect of ischemic cerebrovascular disease, and to provide new thought for the treatment of chronic cerebrovascular disorder.


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 120 participants
Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration: 6 Months
Official Title: Relationship Between Endothelial Progenitor Cells and Revascularization Effect of Moyamoya Disease
Actual Study Start Date : September 1, 2017
Estimated Primary Completion Date : September 1, 2019
Estimated Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine


Group/Cohort
Moyamoya disease patients
Moyamoya disease patients/Healthy volunteers



Primary Outcome Measures :
  1. Expression of endothelial progenitor cells and endothelial cells in peripheral blood [ Time Frame: 2017.9-2018.8 ]
    Expression of endothelial progenitor cells and endothelial cells in peripheral



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Health volunteers' inclusion criteria:

  1. Age between 18-60;
  2. Male or female;

Exclusion criteria:

Exclude the volunteers with history of cerebrovascular disease and heart disease.

Criteria

Inclusion Criteria:

  1. Whole-brain vessels angiography or magnetic resonance arteriography (MRA) has the following manifestations: stenosis or occlusion of terminal internal carotid artery or the anterior cerebral artery and/or initiating middle cerebral artery; In the arterial phase, the abnormal smokey vascular net near the occlusive or stenosis lesion can be seen.
  2. For patients with stable stroke, there was no acute or subacute cerebral infarction or cerebral hemorrhage, and at least 3 months before the last cerebral infarction or cerebral hemorrhage events.

Exclusion Criteria:

  1. Exclude atherosclerosis, autoimmune diseases, meningitis, intracranial tumors, multiple neurofibromatosis, Down syndrome, craniocerebral trauma, radiation injury, and other underlying diseases that may cause smoke.
  2. Acute or subacute cerebral infarction or cerebral hemorrhage were excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03613701


Contacts
Layout table for location contacts
Contact: Lian Duan, Chief 0086-10-66947156 keyan307@163.com

Locations
Layout table for location information
China, Beijing
The 307th Hospital of Military Chinese People's Liberation Army Recruiting
Beijing, Beijing, China, 100071
Contact: Lian Duan, Chief    0086-10-66947156    keyan307@163.com   
Sponsors and Collaborators
Affiliated Hospital to Academy of Military Medical Sciences
Investigators
Layout table for investigator information
Study Chair: Lian Duan, Chief The 307th Hospital of Military Chinese People's Liberation Army

Additional Information:

Layout table for additonal information
Responsible Party: Affiliated Hospital to Academy of Military Medical Sciences
ClinicalTrials.gov Identifier: NCT03613701     History of Changes
Other Study ID Numbers: 8157113
First Posted: August 3, 2018    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Affiliated Hospital to Academy of Military Medical Sciences:
Moyamoya disease
Endothelial progenitor cells
revascularization
Additional relevant MeSH terms:
Layout table for MeSH terms
Carotid Artery Diseases
Cerebral Arterial Diseases
Intracranial Arterial Diseases
Arterial Occlusive Diseases
Moyamoya Disease
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases